Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Urticaria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Chronic Urticaria. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-003686-13 Sponsor Protocol Number: P04805-V2.0 Start Date*: 2007-05-31
    Sponsor Name:Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin
    Full Title: An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in p...
    Medical condition: Chronic urticaria is characterized by the spontaneous development of wheal and flare type skin reactions.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009159 Chronic urticaria LLT
    9.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003018-11 Sponsor Protocol Number: CQGE031E12301 Start Date*: 2021-10-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolesce...
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10008675 Cholinergic urticaria LLT
    23.0 10040785 - Skin and subcutaneous tissue disorders 10012521 Dermographism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) SI (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005404-13 Sponsor Protocol Number: CIGE025ADE05 Start Date*: 2007-01-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE a...
    Medical condition: chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018716-33 Sponsor Protocol Number: PHRN09-AM/MUCIS Start Date*: 2010-10-21
    Sponsor Name:CHRU de TOURS
    Full Title: Etude de l'efficacité du méthotrexate en adjonction d'un anti-histaminique H1 dans le traitement de l'urticaire chronique idiopathique sévère réfractaire aux anti-H1 seuls : essai randomisé.
    Medical condition: urticaire chronique idiopathique sévère
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024113-31 Sponsor Protocol Number: CUN-OMAL-CU-2010 Start Date*: 2011-08-08
    Sponsor Name:Instituto Científico y Tecnológico de Navarra
    Full Title: Ensayo clínico multicéntrico, doble ciego, controlado con placebo, cruzado (2x2) con aleatorización de la secuencia, para evaluar la eficacia y seguridad de Omalizumab (Xolair®, Novartis) en una nu...
    Medical condition: Pacientes con urticaria crónica grave que no responden a dosis aprobadas de antihistamínicos
    Disease: Version SOC Term Classification Code Term Level
    13 10009159 Urticaria crónica LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002308-15 Sponsor Protocol Number: P160913 Start Date*: 2018-11-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: COrticosteroids in acUte uRticAria in emerGency dEpartment
    Medical condition: Adults patients with isolated acute urticaria presenting to the emergency department
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001106 Acute urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004254-25 Sponsor Protocol Number: CIGE025EDE16 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures...
    Medical condition: moderate to severe chronic spontaneous urticaria with angioedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009498-87 Sponsor Protocol Number: Q4577g Start Date*: 2009-06-25
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anith...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009159 Chronic urticaria LLT
    9.1 10021247 Idiopathic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001245-33 Sponsor Protocol Number: BILA 2006/UCI Start Date*: 2006-07-31
    Sponsor Name:FAES FARMA S.A.
    Full Title: “Estudio en fase III, doble ciego, randomizado, controlado con placebo, comparativo de la eficacia y seguridad de bilastina 20 mg una vez al día y levocetirizina 5 mg para el tratamiento de la ...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021247 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002749-38 Sponsor Protocol Number: BT0800NED001 Start Date*: 2007-07-18
    Sponsor Name:Barrier Therapeutics nv
    Full Title: A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria
    Medical condition: Chronic Idiopathic Urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005746-22 Sponsor Protocol Number: AECUDATT Start Date*: 2009-05-05
    Sponsor Name:Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin
    Full Title: Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)
    Medical condition: Chronic urticaria is characterized by the spontaneous development of wheal and flare type skin reactions.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009869 Cold urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000169-17 Sponsor Protocol Number: D3259C00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneo...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012013-22 Sponsor Protocol Number: BILA-3009/PED Start Date*: 2009-12-09
    Sponsor Name:FAES FARMA S.A.
    Full Title: A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children from 2 to <12 Years of age with Allergic Rhinoconjunctivitis or Chronic Ur...
    Medical condition: Allergic Rhinoconjunctivitis and chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001728 Allergic rhinoconjunctivitis LLT
    12.0 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003636-13 Sponsor Protocol Number: CQGE031C2201E1 Start Date*: 2016-01-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQG...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006447-95 Sponsor Protocol Number: CDX0159-07 Start Date*: 2022-09-09
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing) LT (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023057-11 Sponsor Protocol Number: DC02/RUP/3/09 Start Date*: 2011-02-09
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: Efficacy and safety of rupatadine solution in the treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Medical condition: Treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003233-15 Sponsor Protocol Number: GX29107 Start Date*: 2013-12-02
    Sponsor Name:Genentech, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled pilot study of quilizumab in patients with refractory chronic spontaneous urticaria (CSU).
    Medical condition: Patients with chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    16.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000771-34 Sponsor Protocol Number: IC010RUP/3/04 Start Date*: 2004-10-28
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: A 6-week multicentre, double-blind, randomised, placebo-controlled, parallel-group study to assess the efficacy and safety of rupatadine 10 and 20 mg in the treatment of Chronic Idiopathic Urticar...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    7 10021247 0
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA